8-K current report · filed Nov 9, 2026

HARROW, INC. (HROW) 8-K Current Report: November 9, 2026

Item 2.02Item 7.01Item EX-99.2Item EX-99.3Item EX-99.1HROW overview

Short answer

HARROW, INC. (HROW) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results for quarter ended September 30, 2026 announced November 9, 2026.

HARROW, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 results for quarter ended September 30, 2026 announced November 9, 2026
  • Stockholder letter includes updates on recent corporate developments
  • Press release and stockholder letter provide the substantive financial details as Exhibits 99.1 and 99.2

Item 7.01 · Regulation FD Disclosure

  • Exhibit 99.3 contains Harrow’s investor presentation for earnings calls, conferences and management meetings
  • Presentation content may provide management’s latest business priorities and investor messaging

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $99.3M, up 39% YoY, led by branded revenue of $83.5M, approximately 84% of total revenue
  • GAAP net income $9.8M benefited from a $5.0M litigation settlement gain, while nine-month net loss reached $35.1M
  • Q3 Adjusted EBITDA $21.2M, down from $22.8M YoY, with full-year guidance cut to more than $40M from $80M-$100M
  • Revenue guidance reaffirmed at $350M-$365M, requiring Q4 revenue acceleration and Q4 Adjusted EBITDA above $33M
  • Cash $75.3M versus $292.7M notes payable, while operating cash flow was negative $27.4M through nine months

Item EX-99.2 · Exhibit EX-99.2

  • Q3 revenue $99.3M, up 39% YoY, led by branded products at $83.5M, up 62%
  • GAAP net income $9.8M included a $5.0M litigation settlement gain, limiting earnings quality
  • 2026 revenue guidance reaffirmed at $350M-$365M, requiring approximately $136M-$151M in Q4 revenue
  • Adjusted EBITDA outlook reduced to a floor above $40M from $80M-$100M, including more than $33M expected in Q4
  • VEVYE coverage expanded to 10+ million commercial lives effective January 1, 2027, supporting prescription volume and pricing potential

Item EX-99.3 · Exhibit EX-99.3

  • Q3 revenue $99.3M, up 41% QoQ and 39% YoY, with adjusted EBITDA $21.2M, up 62% YoY
  • FY2026 revenue outlook reaffirmed at $350M-$365M, requiring implied Q4 revenue of $135.8M-$150.8M
  • VEVYE revenue $39.7M, up 75% YoY, supported by 83% TRx growth and expanded PBM coverage effective January 1, 2027
  • TYRVAYA acquisition closed October 2026 for $30M upfront plus up to $70M in net-sales milestones, with over $30M 2027 revenue expected
  • G-MELT NDA submission expected November/December 2026, advancing a potential 2028 launch in cataract-surgery sedation

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other HARROW, INC. 8-K filings

Get the next HROW 8-K as it lands

Follow HROW for push alerts, or ask the research agent what this filing means.